

Schizophrenia – Pipeline Assessment and Insights

Reference No.: **PSRCXXXGPR**

Publication Date: **April 2018**

Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Schizophrenia Disease

2.1 Disease Overview

- 2.1.1 Disease Definition
- 2.1.2 Disease Epidemiology
- 2.1.3 Current Treatment Options
- 2.1.4 Key unmet needs

3 Pipeline Assessment

3.1 Overview

3.2 Strategic Review of the Pipeline

3.3 Pipeline analysis by Phases of Development

- 3.3.1 NDA/BLA Filed
- 3.3.2 Phase III Pipeline
- 3.3.3 Phase II Pipeline
- 3.3.4 Phase I Pipeline
- 3.3.5 Preclinical Pipeline
- 3.3.6 Discovery Pipeline

3.4 Pipeline Analysis by Mechanism of Action

3.5 Pipeline Analysis by Novelty of Mechanism of Action

3.6 Suspended and Terminated products

3.7 Schizophrenia – Promising Therapies in Pipeline

- 3.7.1 ALKS 3831
 - 3.7.1.1 Overview
 - 3.7.1.2 Research & Development Key Milestones
 - 3.7.1.3 Efficacy
 - 3.7.1.4 Safety
 - 3.7.1.5 Dosing Frequency and Formulation
 - 3.7.1.6 Potential Clinical Positioning
 - 3.7.1.7 Potential Commercial Positioning
 - 3.7.1.8 Pricing and Reimbursement

3.7.2 MIN-101

- 3.7.2.1 Overview
- 3.7.2.2 Research and development key milestones
- 3.7.2.3 Efficacy
- 3.7.2.4 Safety
- 3.7.2.5 Dosing Frequency and Formulation
- 3.7.2.6 Potential Clinical Positioning
- 3.7.2.7 Potential Commercial Positioning
- 3.7.2.8 Pricing and Reimbursement

3.7.3 Lumateperone

- 3.7.3.1 Overview
- 3.7.3.2 Research and development key milestones
- 3.7.3.3 Efficacy
- 3.7.3.4 Safety
- 3.7.3.5 Dosing Frequency and Formulation
- 3.7.3.6 Potential Clinical Positioning
- 3.7.3.7 Potential Commercial Positioning
- 3.7.3.8 Pricing and Reimbursement

3.7.4 Nuplazid

- 3.7.4.1 Overview
- 3.7.4.2 Research and development key milestones
- 3.7.4.3 Efficacy
- 3.7.4.4 Safety
- 3.7.4.5 Dosing Frequency and Formulation
- 3.7.4.6 Potential Clinical Positioning
- 3.7.4.7 Potential Commercial Positioning
- 3.7.4.8 Pricing and Reimbursement

3.7.5 SEP-363856

- 3.7.5.1 Overview
- 3.7.5.2 Research and development key milestones
- 3.7.5.3 Efficacy
- 3.7.5.4 Safety
- 3.7.5.5 Dosing Frequency and Formulation
- 3.7.5.6 Potential Clinical Positioning
- 3.7.5.7 Potential Commercial Positioning
- 3.7.5.8 Pricing and Reimbursement

3.7.6 ASP4345

- 3.7.6.1 Overview
- 3.7.6.2 Research and development key milestones
- 3.7.6.3 Efficacy

Table of Contents

- 3.7.6.4 Safety
- 3.7.6.5 Dosing Frequency and Formulation
- 3.7.6.6 Potential Clinical Positioning
- 3.7.6.7 Potential Commercial Positioning
- 3.7.6.8 Pricing and Reimbursement

3.7.7 TAK-831

- 3.7.7.1 Overview
- 3.7.7.2 Research and development key milestones
- 3.7.7.3 Efficacy
- 3.7.7.4 Safety
- 3.7.7.5 Dosing Frequency and Formulation
- 3.7.7.6 Potential Clinical Positioning
- 3.7.7.7 Potential Commercial Positioning
- 3.7.7.8 Pricing and Reimbursement

4 Appendix

- 4.1 Coverage**
- 4.2 Methodology and Research conducted**
- 4.3 About Pharmascroll**
- 4.4 Contact Us**
- 4.5 Disclaimer**